| Excerpt | Reference | Relevance |
|---|
| " There were no major adverse events with either drug." | ( Efficacy and safety of CGP 56697 (artemether and benflumetol) compared with chloroquine to treat acute falciparum malaria in Tanzanian children aged 1-5 years.
Abdulla, S; Beck, HP; Gathmann, I; Hatz, C; Kibatala, P; Mull, R; Royce, C; Schellenberg, D; Tanner, M, 1998) | 0.3 |
| " Adverse events were mostly mild." | ( Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria.
de Palacios, PI; Falade, C; Makanga, M; Ortmann, CE; Premji, Z; Stockmeyer, M, 2005) | 0.33 |
| " Adverse events and clinical and parasitological outcomes were recorded." | ( A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda.
D'Alessandro, U; Fanello, CI; Karema, C; Ngamije, D; van Doren, W; Van Overmeir, C, 2007) | 0.34 |
| " Treatment was well tolerated; most adverse events were mild to moderate and seemed to be related to malaria." | ( Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study.
Andriano, K; Bricaire, F; Burchard, GD; De Palacios, PI; Gay, F; Genton, B; Hatz, C; Lefèvre, G; Loutan, L; Nothdurft, HD; Soto, J; Weitzel, T; Zoller, T, 2008) | 0.35 |
| " Participants were actively monitored for adverse events for the first 14 days after each treatment, and then passively followed until their next study medication treatment, or withdrawal from study." | ( Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children.
Clark, TD; Dorsey, G; Jagannathan, P; Kamya, MR; Maiteki-Sebuguzi, C; Njama-Meya, D; Nzarubara, B; Rosenthal, PJ; Staedke, SG; Talisuna, AO; Yau, VM, 2008) | 0.35 |
| " The incidence of adverse events, such as pruritus, fatigue and neutropaenia were similar in the two treatment groups." | ( Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up.
Adjei, GO; Alifrangis, M; Badoe, EV; Goka, BQ; Hoegberg, LC; Kitcher, ED; Kurtzhals, JA; Lamptey, R; Rodrigues, OP, 2008) | 0.35 |
| "AS+AQ and AM-L were efficacious for treatment of children with uncomplicated malaria in Ghana and drug-related adverse events were rare in treated subjects during one year of follow-up." | ( Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up.
Adjei, GO; Alifrangis, M; Badoe, EV; Goka, BQ; Hoegberg, LC; Kitcher, ED; Kurtzhals, JA; Lamptey, R; Rodrigues, OP, 2008) | 0.35 |
| " The most common drug-related adverse event was vomiting (n=33 [7%] and n=42 [9%], respectively)." | ( Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial.
Abdulla, S; Andriano, K; Bassat, Q; Beck, HP; Björkman, A; Borrmann, S; Cousin, M; D'Alessandro, U; González, R; Hamel, M; Juma, E; Lefèvre, G; Lyimo, J; Maiga, H; Mårtensson, A; Nahum, A; Ogutu, B; Otieno, L; Premji, Z; Sagara, I; Sasi, P; Ubben, D, 2008) | 0.35 |
| " The six-dose regimen of AL was well tolerated with no drug-related serious adverse events." | ( Evaluation of the efficacy and safety of artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in Nigerian infants and children.
Dada-Adegbola, HO; de Palacios, PI; Falade, AG; Falade, CO; Hunt, P; Oduola, AM; Ogunkunle, OO; Salako, LA; Virtanen, M, 2008) | 0.35 |
| "The six-dose regimen of AL tablets is safe and effective for the treatment of acute uncomplicated malaria in Nigerian infants and children weighing between five and 25 kg." | ( Evaluation of the efficacy and safety of artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in Nigerian infants and children.
Dada-Adegbola, HO; de Palacios, PI; Falade, AG; Falade, CO; Hunt, P; Oduola, AM; Ogunkunle, OO; Salako, LA; Virtanen, M, 2008) | 0.35 |
| " Most common drug-related adverse events were gastrointestinal symptoms (such as vomiting and diarrhea) which were slightly higher in the AS-SMP 24-hour group." | ( Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial.
Adam, I; Dara, N; Dicko, A; Dicko, YT; Djimdé, A; Doumbo, OK; Jansen, FH; Maiga, H; Mbacham, W; Rulisa, S; Sagara, I; Sissoko, K; Traore, OB, 2009) | 0.35 |
| " Adverse effects, clinical response (treatment failure) and parasitological response were compared." | ( A randomized clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda.
Kaye, DK; Mutyaba, TS; Ndeezi, G; Nshemerirwe, R, 2008) | 0.35 |
| " The adverse effects were comparable between the two groups." | ( A randomized clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda.
Kaye, DK; Mutyaba, TS; Ndeezi, G; Nshemerirwe, R, 2008) | 0.35 |
| " The majority of the reported adverse events seen in these studies are mild or moderate in severity and tend to affect the gastrointestinal or nervous systems." | ( Safety profile of Coartem: the evidence base.
Falade, C; Manyando, C, 2009) | 0.35 |
| " Participants were actively monitored for adverse events for 28 days and then passively for up to 63 days after treatment." | ( Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children.
Arinaitwe, E; Bigira, V; Dorsey, G; Gasasira, A; Homsy, J; Kakuru, A; Kamya, MR; Katrak, S; Sandison, TG; Tappero, JW; Wanzira, H, 2009) | 0.35 |
| " Most adverse events were rare, with only cough, diarrhoea, vomiting, and anaemia occurring in more than 1% of treatments." | ( Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children.
Arinaitwe, E; Bigira, V; Dorsey, G; Gasasira, A; Homsy, J; Kakuru, A; Kamya, MR; Katrak, S; Sandison, TG; Tappero, JW; Wanzira, H, 2009) | 0.35 |
| "Both AL and DP were safe and well tolerated for the treatment of uncomplicated malaria in young HIV-infected and uninfected children." | ( Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children.
Arinaitwe, E; Bigira, V; Dorsey, G; Gasasira, A; Homsy, J; Kakuru, A; Kamya, MR; Katrak, S; Sandison, TG; Tappero, JW; Wanzira, H, 2009) | 0.35 |
| " Three distinct channels for identification of adverse events (AEs) and serious adverse events (SAEs) were identified and implemented." | ( Experience of safety monitoring in the context of a prospective observational study of artemether-lumefantrine in rural Tanzania: lessons learned for pharmacovigilance reporting.
Genton, B; Kabanywanyi, AM; Lengeler, C; Malila, A; Migoha, C; Mulure, N; Schlienger, R, 2010) | 0.36 |
| " There were 290 adverse events in the quinine group and 141 in the artemether-lumefantrine group." | ( Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial.
Ashley, EA; Dhorda, M; Guerin, PJ; Lindegardh, N; McGready, R; Nabasumba, C; Nosten, F; Nyehangane, D; Piola, P; Snounou, G; Turyakira, E, 2010) | 0.36 |
| "04), there were no differences between treatment arms in the occurrence of adverse events." | ( Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children.
Chaponda, M; D'Alessandro, U; Hachizovu, S; Mukwamataba, D; Mulenga, M; Nambozi, M; Ubben, D; Van Geertruyden, JP, 2011) | 0.37 |
| "DHA/PQP was as efficacious, safe and well tolerated in treatment of uncomplicated malaria as AL, though in the latter group more new infections during the follow up were observed." | ( Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children.
Chaponda, M; D'Alessandro, U; Hachizovu, S; Mukwamataba, D; Mulenga, M; Nambozi, M; Ubben, D; Van Geertruyden, JP, 2011) | 0.37 |
| "To assess the in vivo efficacy and adverse effects of Artemether-lumefantrine combination in acute uncomplicated falciparum malaria." | ( Efficacy and safety of artemehter-lumefantrine in uncomplicated falciparum malaria in Liberia.
Ahmad, K; Awan, MY; Khan, SM; Khurshid, U; Rasheed, A, 2011) | 0.37 |
| " Frequency of various adverse events observed during this study were also noted." | ( Efficacy and safety of artemehter-lumefantrine in uncomplicated falciparum malaria in Liberia.
Ahmad, K; Awan, MY; Khan, SM; Khurshid, U; Rasheed, A, 2011) | 0.37 |
| " The results support the continued safe and efficacious use of artemether-lumefantrine in uncomplicated falciparum malaria." | ( Randomized, prospective, three-arm study to confirm the auditory safety and efficacy of artemether-lumefantrine in Colombian patients with uncomplicated Plasmodium falciparum malaria.
Barón, C; Carrasquilla, G; Cousin, M; Fisher, LM; Lefèvre, G; Monsell, EM; Sander, O; Walter, V, 2012) | 0.38 |
| " In the second and third trimesters, AL was not associated with increased adverse pregnancy outcomes as compared with quinine or sulphadoxine-pyrimethamine, showed improved tolerability relative to quinine, and its efficacy was non-inferior to quinine." | ( A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy.
D'Alessandro, U; Hamed, K; Juma, E; Kayentao, K; Manyando, C; Okafor, HU, 2012) | 0.38 |
| " The use of RDTs, amoxicillin, and AL was associated with few minor adverse events." | ( Quality and safety of integrated community case management of malaria using rapid diagnostic tests and pneumonia by community health workers.
Brooks, ET; Hamer, DH; MacLeod, WB; Pilingana, P; Sabin, LL; Semrau, K; Siazeele, K; Thea, DM; Yeboah-Antwi, K, 2012) | 0.38 |
| "Four thousand, seven hundred and twenty six adverse events (AEs) were recorded in 6,000 patients receiving AL." | ( Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review.
Egunsola, O; Oshikoya, KA, 2013) | 0.39 |
| "Artemether-lumefantrine combination is as safe as ASAQ and DP for use in children." | ( Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review.
Egunsola, O; Oshikoya, KA, 2013) | 0.39 |
| " Trial harm and tolerability assessments rely, in part, on participants' reports of medical histories, adverse events (AEs), and concomitant medications." | ( How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral interaction trials.
Allen, EN; Barnes, KI; Chandler, CI; Lemnge, M; Massawe, IS; Mehta, U; Mushi, AK; Staedke, SG; Vestergaard, LS, 2013) | 0.39 |
| "Questioning methods and trial contexts influence the detection of adverse events, medical histories and concomitant medications." | ( How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral interaction trials.
Allen, EN; Barnes, KI; Chandler, CI; Lemnge, M; Massawe, IS; Mehta, U; Mushi, AK; Staedke, SG; Vestergaard, LS, 2013) | 0.39 |
| " All the other adverse events reported were mild, and no significant difference was noted by treatment." | ( Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Re
Djallé, D; Laganier, R; Le Faou, A; Manirakiza, A; Njuimo, SP; Rogier, C, 2014) | 0.4 |
| " Incidence of adverse events was related to underlying disease; malaria being reported in both treatment arms." | ( Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study.
Akhwale, W; Eyase, F; Johnson, JD; Juma, E; Koskei, N; Obonyo, C; Ogutu, BR; Omollo, R; Omondi, EK; Ongecha, JM; Onyango, KO; Otieno, GA; Otieno, L; Perkins, DJ, 2014) | 0.4 |
| " Quinine exposure was associated with adverse pregnancy outcomes which was not the case following other anti-malarial intake." | ( Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort.
Abdulla, S; Genton, B; Mazuguni, F; Mosha, D; Mrema, S; Sevene, E, 2014) | 0.4 |
| " No statistical significant differences were observed in the occurrence of adverse events among treatment groups." | ( Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children.
Ali, IM; Chedjou, JP; Ekollo, AM; Evehe, MS; Froeschl, G; Heumann, C; Mansmann, U; Mbacham, WF; Moyeh, MN; Ndikum, VN; Ngongang, EO; Nji, AM; Ogundahunsi, O, 2015) | 0.42 |
| " The cumulative risk of recurrent malaria within 84 days and the risk of adverse events within 28 days were compared across study arms using a Cox proportional hazards model and generalized estimating equations, respectively." | ( Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria in the setting of three different chemopreventive regimens.
Achan, J; Bigira, V; Clark, T; Dorsey, G; Kamya, M; Kapisi, J; Kinara, S; Mwangwa, F; Soremekun, S, 2015) | 0.42 |
| " Compared to the no chemoprevention arm, none of the chemopreventive regimens were associated with an increased risk of adverse events following treatment of malaria with AL." | ( Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria in the setting of three different chemopreventive regimens.
Achan, J; Bigira, V; Clark, T; Dorsey, G; Kamya, M; Kapisi, J; Kinara, S; Mwangwa, F; Soremekun, S, 2015) | 0.42 |
| " In the setting of chemoprevention, treatment of uncomplicated malaria with AL was safe and efficacious, with moderate protection against recurrent malaria among children assigned monthly DP." | ( Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria in the setting of three different chemopreventive regimens.
Achan, J; Bigira, V; Clark, T; Dorsey, G; Kamya, M; Kapisi, J; Kinara, S; Mwangwa, F; Soremekun, S, 2015) | 0.42 |
| " Follow-up visits were performed on days 3, 7, 14, 21, and 28 to evaluate clinical and parasitological resolution of their malaria episode as well as adverse events." | ( Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial.
Derra, K; Diallo-Nakanabo, S; Guiguemde, TR; Kazienga, A; Ouedraogo, JB; Owusu-Dabo, E; Sondo, P; Sorgho, H; Tarnagda, Z; Tinto, H; Valea, I; Zampa, O, 2015) | 0.42 |
| " Adverse events were reported in four (3." | ( Surveillance for the safety and effectiveness of artemether-lumefantrine in patients with uncomplicated Plasmodium falciparum malaria in the USA: a descriptive analysis.
Arguin, PM; Gray, AM; Hamed, K, 2015) | 0.42 |
| " The primary endpoint was the PCR-corrected adequate clinical and parasitological response (ACPR) at day 28 (D28); the secondary endpoints included ACPR at D42, clearance times for parasites, fever, and gametocytes, and the incidence of adverse events." | ( [Evaluation of the efficacy and safety of three 2-drug combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Senegal: artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine].
Abiola, A; Ba, MS; Dieng, Y; Faye, B; Gaye, O; Lo, AC; Ndiaye, JL; Ndiaye, M; Pene, M; Seck, A; Sow, D; Sylla, K; Tine, RC, ) | 0.13 |
| " The combinations were well tolerated, with no serious adverse events reported during the follow-up period." | ( [Evaluation of the efficacy and safety of three 2-drug combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Senegal: artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artemether-lumefantrine].
Abiola, A; Ba, MS; Dieng, Y; Faye, B; Gaye, O; Lo, AC; Ndiaye, JL; Ndiaye, M; Pene, M; Seck, A; Sow, D; Sylla, K; Tine, RC, ) | 0.13 |
| "Patients who presented to public health facilities in four regions of Tanzania who were prescribed AL were enrolled in a CEM study, a prospective, observational cohort study to establish a profile of adverse events (AEs) for the medicine when used in routine clinical practice." | ( Safety Profile of Artemether-Lumefantrine: A Cohort Event Monitoring Study in Public Health Facilities in Tanzania.
Fimbo, AM; Hill, G; Irunde, HF; Minzi, OM; Mssusa, AK; Nkayamba, AF; Shewiyo, DH; Sillo, HB, 2016) | 0.43 |
| " The AE profile was consistent with the AEs reported in the product information and in other studies; no new adverse drug reactions were identified." | ( Safety Profile of Artemether-Lumefantrine: A Cohort Event Monitoring Study in Public Health Facilities in Tanzania.
Fimbo, AM; Hill, G; Irunde, HF; Minzi, OM; Mssusa, AK; Nkayamba, AF; Shewiyo, DH; Sillo, HB, 2016) | 0.43 |
| " A majority of the adverse events (AEs) were mild and unrelated to the study drugs." | ( Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania.
Björkman, A; Gosling, R; Jovel, I; Mårtensson, A; Mmbando, BP; Mwaiswelo, R; Ngasala, BE; Poirot, E; Premji, Z, 2016) | 0.43 |
| "The Primaquine Roll Out Monitoring Pharmacovigilance Tool (PROMPT), comprising: (1) a standardized form to support the surveillance of possible adverse events following SLD PQ treatment; (2) a patient information card to enhance awareness of known adverse drug reactions of SLD PQ use; and (3) a database compiling recorded information, was developed and piloted." | ( Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study.
Brown, J; Darteh, S; Gosling, R; Hwang, J; Kunene, S; Malambe, C; Maphalala, G; Mkhonta, N; Mwandemele, A; Ntshalintshali, N; Pace, C; Pan, S; Poirot, E; Soble, A; Stergachis, A; Vilakati, S; Vittinghoff, E, 2016) | 0.43 |
| " Of the 11 (11 %) patients who reported an adverse event over the study period, three were considered serious and included two deaths and one hospitalization; none were causally related to SLD PQ." | ( Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study.
Brown, J; Darteh, S; Gosling, R; Hwang, J; Kunene, S; Malambe, C; Maphalala, G; Mkhonta, N; Mwandemele, A; Ntshalintshali, N; Pace, C; Pan, S; Poirot, E; Soble, A; Stergachis, A; Vilakati, S; Vittinghoff, E, 2016) | 0.43 |
| " The drug was well tolerated, and no adverse event related to the drug was reported." | ( Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria at sentinel sites in Mozambique, 2015.
Candrinho, B; De Carvalho, E; Enosse, S; Matsinhe, F; Muthemba, R; Namboze, J; Naueia, E; Rafael, B; Sacarlal, J; Salvador, C; Tiago, A; Warsame, M, 2017) | 0.46 |
| " Dizziness, nausea, vomiting, headache and asthenia as adverse events (AEs) were more common in MQAS than in AL or DHAPQ (p < 0." | ( Artemisinin-based combination therapy in pregnant women in Zambia: efficacy, safety and risk of recurrent malaria.
Buyze, J; D'Alessandro, U; Hachizovu, S; Kabuya, JB; Kasongo, W; Mulenga, J; Mulenga, M; Mwakazanga, D; Nambozi, M; Van Geertruyden, JP, 2017) | 0.46 |
| " Both the treatments were found to be safe and well tolerated." | ( Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Rando
Anvikar, AR; Behra, N; Das, RR; Gaye, O; Jalali, RK; Maheshwar, AV; Mishra, P; Mwapasa, V; Nasa, A; Roy, A; Sagara, I; Sharma, P; Sharma, SK; Thompson, R; Toure, OA; Tshefu, AK; Valecha, N, 2017) | 0.46 |
| " Adverse events ranged from mild to moderate severity but were not directly attributed to drug intake." | ( Monitoring the Efficacy and Safety of Artemisinin-Based Combination Therapies: A Review and Network Meta-analysis of Antimalarial Therapeutic Efficacy Trials in Cameroon.
Basco, LK; Chiabi, A; Whegang Youdom, S, 2019) | 0.51 |
| "ACTs are still effective and safe in Cameroon; however, there are insufficient data on their efficacy, safety and tolerability, therefore more RCTs should be conducted, including novel ACTs." | ( Monitoring the Efficacy and Safety of Artemisinin-Based Combination Therapies: A Review and Network Meta-analysis of Antimalarial Therapeutic Efficacy Trials in Cameroon.
Basco, LK; Chiabi, A; Whegang Youdom, S, 2019) | 0.51 |
| " Common adverse events included cough, abdominal pain, vomiting, and diarrhoea." | ( Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania.
Chacky, F; Francis, F; Greer, G; Halsey, ES; Ishengoma, DS; Kabanywanyi, AM; Kamugisha, E; Kavishe, RA; Kitojo, CA; Lucchi, NW; Mahende, MK; Mandara, CI; Mandike, R; Martin, T; Mkude, S; Mohamed, A; Muro, F; Ngasala, B; Njau, R; Paxton, L; Talundzic, E; Udhayakumar, V; Venkatesan, M; Warsame, M, 2019) | 0.51 |
| " Day-42 adequate clinical and parasitological response (ACPR) and incidence of adverse events was assessed in HIV-infected individuals on efavirenz-based ART with uncomplicated falciparum malaria treated with AL." | ( Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial.
Banda, CG; Chaponda, M; Hachizovu, S; Kabuya, JB; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Mukaka, M; Mulenga, J; Mulenga, M; Mwapasa, V; Sikalima, J; Terlouw, DJ, 2019) | 0.51 |
| " There were only two cases of grade 3 neutropaenia and one serious adverse event of lobar pneumonia, none of which was judged as probably related to intake of AL." | ( Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial.
Banda, CG; Chaponda, M; Hachizovu, S; Kabuya, JB; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Mukaka, M; Mulenga, J; Mulenga, M; Mwapasa, V; Sikalima, J; Terlouw, DJ, 2019) | 0.51 |
| " Day 7 lumefantrine concentrations and the number and nature of adverse events were similar between study arms; only one serious adverse event occurred (renal impairment in the no primaquine arm)." | ( Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial.
Allen, E; Barnes, KI; Frean, J; Mabuza, A; Malatje, G; Raman, J; Swanepoel, H; Wiesner, L; Workman, L, 2019) | 0.51 |
| " Adverse events and serious adverse events were rarely observed with both treatments." | ( Persistence of High In Vivo Efficacy and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine as the First- and Second-Line Treatments for Uncomplicated Plasmodium falciparum Malaria 10 Years After Their Implementation in Gabon.
Bouyou-Akotet, MK; Fandeur, T; Koumba Lengongo, JV; Lekana-Douki, JB; M'Bondoukwé, NP; Mawili-Mboumba, DP; Moutombi Ditombi, B; Ndong Ngomo, JM; Offouga, CL; Ondzagha Megnie, GJ; Ringwald, P, 2019) | 0.51 |
| "0%) patients experienced at least one drug-related adverse event (AE)." | ( Safety and tolerability of artesunate-amodiaquine, artemether-lumefantrine and quinine plus clindamycin in the treatment of uncomplicated Plasmodium falciparum malaria in Kinshasa, the Democratic Republic of the Congo.
Fungula, B; Inocencio da Luz, R; Kalabuanga, M; Lula Ntamba, Y; Lutumba, P; Muhindo Mavoko, H; Ntamabyaliro Nsengi, PM; Tona Lutete, G; Van Geertruyden, JP, 2019) | 0.51 |
| " The most frequent adverse event in both groups was asthenia." | ( Monitoring of efficacy, tolerability and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial.
Adegbite, BR; Adegnika, AA; Agnandji, ST; Dejon-Agobe, JC; Edoa, JR; Honkpehedji, YJ; Koehne, E; Kreidenweiss, A; Kremsner, PG; Kun, J; Lalremruata, A; Lell, B; Lotola-Mougueni, F; Mbong-Ngwese, M; Mombo-Ngoma, G; Mordmüller, B; Nguyen, TT; Obone Atome, FA; Ramharter, M; Safiou, AR; Velavan, TP; Zinsou, FJ, 2019) | 0.51 |
| "This study showed that AL and AS-AQ remain efficacious, well-tolerated, and are safe to treat uncomplicated malaria in children from Lambaréné." | ( Monitoring of efficacy, tolerability and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambaréné, Gabon: an open-label clinical trial.
Adegbite, BR; Adegnika, AA; Agnandji, ST; Dejon-Agobe, JC; Edoa, JR; Honkpehedji, YJ; Koehne, E; Kreidenweiss, A; Kremsner, PG; Kun, J; Lalremruata, A; Lell, B; Lotola-Mougueni, F; Mbong-Ngwese, M; Mombo-Ngoma, G; Mordmüller, B; Nguyen, TT; Obone Atome, FA; Ramharter, M; Safiou, AR; Velavan, TP; Zinsou, FJ, 2019) | 0.51 |
| " The secondary criteria were the clearing time of fever, parasites, and gametocytes and then the occurrence of adverse events." | ( [Safety and Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine in Niger].
Adehossi, E; Boureima, S; Hadiza, J; Hamidou, HH; Harouna, HK; Ibrahima, I; Laminou, IM; Mahamadou, A; Maman, D; Tidjani, IA; Yacouba, I, 2020) | 0.56 |
| " There were no clinically relevant toxicities nor adverse events in both control and test arms." | ( Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
Abideen, G; Adeniji, H; Adeuja, O; Agbaje, EO; Akanmu, AS; Akinleye, MO; Akinyede, AA; Busari, AW; Hassan, OO; Ken-Owotor, C; Kogbe, S; Ogunfowokan, T; Onwujuobi, AG; Oreagba, IA; Owolabi, ET; Usman, SO, 2020) | 0.56 |
| " The proportions of non-clinical hepatic adverse events (AEs) following first and repeated treatments with PA and AL were compared within study arms." | ( Hepatic safety of repeated treatment with pyronaridine-artesunate versus artemether-lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso.
Barry, N; Compaoré, YD; Djimdé, A; Kaboré, TN; Kabré, Z; Nikiéma, F; Ouattara, A; Ouédraogo, JB; Sagara, I; Somé, AF; Wermi, K; Yerbanga, RS; Zongo, I; Zongo, M, 2021) | 0.62 |
| " Both treatments were safe and well-tolerated." | ( Efficacy and safety of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ugandan children: a systematic review and meta-analysis of randomized control trials.
Assefa, DG; Bekele, D; Getachew, E; Joseph, M; Manyazewal, T; Tesfahunei, HA; Zeleke, ED, 2021) | 0.62 |
| "The present meta-analysis suggests that artemether-lumefantrine therapy is efficacious and safe in treating uncomplicated falciparum malaria in Ethiopia." | ( Efficacy and safety of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ethiopia: a systematic review and meta-analysis.
Abamecha, A; Abdissa, A; Adissu, W; Yewhalaw, D; Yilma, D, 2021) | 0.62 |
| " Reactive focal mass drug administration (rfMDA) may be safe and more effective." | ( Effectiveness and safety of reactive focal mass drug administration (rfMDA) using dihydroartemisinin-piperaquine to reduce malaria transmission in the very low-endemic setting of Eswatini: a pragmatic cluster randomised controlled trial.
Baltzell, K; Benjamin-Chung, J; Bhangu, K; Dlamini, B; Dlamini, N; Dufour, MK; Gosling, R; Greenhouse, B; Helb, D; Hsiang, MS; Kalungero, M; Kunene, S; Malambe, C; Maphalala, G; Mngadi, N; Nhlabathi, N; Ntshalintshali, N; Pindolia, D; Prach, LM; Tesfa, G; Vilakati, S; Whittemore, B, 2021) | 0.62 |
| " No serious adverse events occurred." | ( Effectiveness and safety of reactive focal mass drug administration (rfMDA) using dihydroartemisinin-piperaquine to reduce malaria transmission in the very low-endemic setting of Eswatini: a pragmatic cluster randomised controlled trial.
Baltzell, K; Benjamin-Chung, J; Bhangu, K; Dlamini, B; Dlamini, N; Dufour, MK; Gosling, R; Greenhouse, B; Helb, D; Hsiang, MS; Kalungero, M; Kunene, S; Malambe, C; Maphalala, G; Mngadi, N; Nhlabathi, N; Ntshalintshali, N; Pindolia, D; Prach, LM; Tesfa, G; Vilakati, S; Whittemore, B, 2021) | 0.62 |
| " Adverse events were documented in less than 2% of participants for both drugs." | ( In vivo efficacy and safety of artemether-lumefantrine and amodiaquine-artesunate for uncomplicated Plasmodium falciparum malaria in Mozambique, 2018.
Aide, P; Bassat, Q; Candrinho, B; Carvalho, E; Chidimatembue, A; Enosse, S; Halsey, ES; Lucchi, N; Macete, E; Mayor, A; Moriarty, LF; Nhacolo, A; Nhama, A; Nhamússua, L; Saifodine, A; Salvador, C; Svigel, SS; Zulliger, R, 2021) | 0.62 |
| "In drug trials, clinical adverse events (AEs), concomitant medication and laboratory safety outcomes are repeatedly collected to support drug safety evidence." | ( Joint modelling of multivariate longitudinal clinical laboratory safety outcomes, concomitant medication and clinical adverse events: application to artemisinin-based treatment during pregnancy clinical trial.
Chapotera, G; Chirwa, T; D'Alessandro, U; Kazembe, L; Laufer, MK; Mathanga, D; Mukaka, M; Mwapasa, V; Patson, N, 2021) | 0.62 |
| " Screening procedure for treatment eligibility and explaining to patients about the possible adverse events was considered very useful for safety reasons." | ( Safety monitoring experience of single-low dose primaquine co-administered with artemether-lumefantrine among providers and patients in routine healthcare practice: a qualitative study in Eastern Tanzania.
Abdulla, S; Drakeley, C; Gosling, R; Kakolwa, MA; Mahende, MK; Masanja, H; Mosha, D; Wamoyi, J, 2021) | 0.62 |
| "Single-low dose primaquine was perceived to be safe and acceptable among providers and patients." | ( Safety monitoring experience of single-low dose primaquine co-administered with artemether-lumefantrine among providers and patients in routine healthcare practice: a qualitative study in Eastern Tanzania.
Abdulla, S; Drakeley, C; Gosling, R; Kakolwa, MA; Mahende, MK; Masanja, H; Mosha, D; Wamoyi, J, 2021) | 0.62 |
| " There were no reported serious adverse events associated with any of the regimens." | ( Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda.
Asua, V; Belay, K; Bosco, A; Bwanika, JB; Ebong, C; Gonahasa, S; Gudoi, S; Halsey, ES; Kamya, MR; Kapisi, J; Kigozi, R; Kyabayinze, D; Lucchi, NW; Moriarty, LF; Mpimbaza, A; Namuganga, JF; Niang, M; Nsobya, SL; Opigo, J; Rubahika, D; Rutazana, D; Sebikaari, G; Souza, SSS; Sserwanga, A; Tibenderana, J; Yeka, A, 2021) | 0.62 |
| "DP remains highly effective and safe for the treatment of uncomplicated malaria in Uganda." | ( Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda.
Asua, V; Belay, K; Bosco, A; Bwanika, JB; Ebong, C; Gonahasa, S; Gudoi, S; Halsey, ES; Kamya, MR; Kapisi, J; Kigozi, R; Kyabayinze, D; Lucchi, NW; Moriarty, LF; Mpimbaza, A; Namuganga, JF; Niang, M; Nsobya, SL; Opigo, J; Rubahika, D; Rutazana, D; Sebikaari, G; Souza, SSS; Sserwanga, A; Tibenderana, J; Yeka, A, 2021) | 0.62 |
| " Safety was based on assessment of adverse events (AEs) and severe adverse events (SAEs) from day 1 to day 28." | ( Effectiveness and safety of artesunate-amodiaquine versus artemether-lumefantrine for home-based treatment of uncomplicated Plasmodium falciparum malaria among children 6-120 months in Yaoundé, Cameroon: a randomized trial.
Aboh, PM; Adzemye, LM; Akam, LF; Ali, IM; Alifrangis, M; Ambani, MCE; Ango, Z; Bigoga, JD; Chedjou, JPK; Dinza, G; Dongmo, CH; Douanla, A; Ewane, MS; Fomboh, CT; Fosah, DA; Kotcholi, GB; Ludovic, AJ; Mbacham, WF; Moyeh, MN; Nana, WD; Ndikum, VN; Ngu, JA; Niba, PTN; Nji, AM; Nna, DRA; Oben, OLA; Omgba, PAM; Selly-Ngaloumo, AA; Tatah, FM; Ticha, JT, 2022) | 0.72 |
| " Expected mild to moderate adverse events were reported in both arms [AS-AQ = 83 (84." | ( Effectiveness and safety of artesunate-amodiaquine versus artemether-lumefantrine for home-based treatment of uncomplicated Plasmodium falciparum malaria among children 6-120 months in Yaoundé, Cameroon: a randomized trial.
Aboh, PM; Adzemye, LM; Akam, LF; Ali, IM; Alifrangis, M; Ambani, MCE; Ango, Z; Bigoga, JD; Chedjou, JPK; Dinza, G; Dongmo, CH; Douanla, A; Ewane, MS; Fomboh, CT; Fosah, DA; Kotcholi, GB; Ludovic, AJ; Mbacham, WF; Moyeh, MN; Nana, WD; Ndikum, VN; Ngu, JA; Niba, PTN; Nji, AM; Nna, DRA; Oben, OLA; Omgba, PAM; Selly-Ngaloumo, AA; Tatah, FM; Ticha, JT, 2022) | 0.72 |
| "This study demonstrated that AS-AQ and AL are effective and safe for home management of malaria in Yaoundé." | ( Effectiveness and safety of artesunate-amodiaquine versus artemether-lumefantrine for home-based treatment of uncomplicated Plasmodium falciparum malaria among children 6-120 months in Yaoundé, Cameroon: a randomized trial.
Aboh, PM; Adzemye, LM; Akam, LF; Ali, IM; Alifrangis, M; Ambani, MCE; Ango, Z; Bigoga, JD; Chedjou, JPK; Dinza, G; Dongmo, CH; Douanla, A; Ewane, MS; Fomboh, CT; Fosah, DA; Kotcholi, GB; Ludovic, AJ; Mbacham, WF; Moyeh, MN; Nana, WD; Ndikum, VN; Ngu, JA; Niba, PTN; Nji, AM; Nna, DRA; Oben, OLA; Omgba, PAM; Selly-Ngaloumo, AA; Tatah, FM; Ticha, JT, 2022) | 0.72 |
| "25 mg/kg single-dose primaquine is safe and sufficient to reduce transmission of gametocytes in individuals with no, reduced, or increased CYP2D6 enzyme activity." | ( A single low dose of primaquine is safe and sufficient to reduce transmission of Plasmodium falciparum gametocytes regardless of cytochrome P450 2D6 enzyme activity in Bagamoyo district, Tanzania.
Kweka, E; Mårtensson, A; Mmbando, BP; Msolo, D; Mwaiswelo, RO; Ngasala, B, 2022) | 0.72 |
| " The intervention was generally well tolerated, with two grade 3 adverse events of neutropenia, and no serious adverse events." | ( Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs.
Barnes, KI; Berghmans, PJ; Chalon, S; Chughlay, MF; El Gaaloul, M; Escoffier, E; Flynn, J; Gobeau, N; Izquierdo-Juncàs, D; Jansen, B; Kümmel, A; Marx, MW; Mitov, V; Möhrle, JJ; Rosanas-Urgell, A; Van Geertruyden, JP; Van Leuven, K, 2022) | 0.72 |
| " No serious adverse events were reported during the 28 days follow-up." | ( Safety and therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria at Shecha health centre, Arba Minch, Ethiopia.
Abay, SM; Assefa, A; Assefa, G; Bekele, W; Gidey, B; Gubae, K; Haile, M; Hailgiorgis, H; Mare, AK; Mohammed, H; Sime, H; Tasew, G, 2023) | 0.91 |
| " Adverse events in both treatment arms were mild and similar to the symptoms of malaria infection." | ( Efficacy and safety of pyronaridine-artesunate versus artemether-lumefantrine in the treatment of acute uncomplicated malaria in children in South-West Nigeria: an open-labelled randomized controlled trial.
Adedapo, AD; Anjorin, OE; Falade, CO; Funwei, RI; Michael, OS; Mokuolu, OA; Olusanya, AL; Olusola, FI; Orimadegun, AE; Orimadegun, BE, 2023) | 0.91 |
| " Mild and moderate adverse events, including gastrointestinal and/or nervous disorders, were reported in 11." | ( Therapeutic efficacy and safety of artesunate + amodiaquine and artemether + lumefantrine in treating uncomplicated Plasmodium falciparum malaria in children on the rainy south-east coast of Madagascar.
Carn, G; Harimanana, AN; Hotahiene, R; Irinantenaina, J; Ralemary, N; Randriamiarinjatovo, DNAL; Randrianarivelojosia, M; Randriarison, M; Razafinjato, C; Razanatsiorimalala, S, 2023) | 0.91 |
| " Artemisinin-based combination treatments are generally well tolerated, safe and effective; the most used being artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP)." | ( Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of
D'Alessandro, U; Dabira, ED; Diakite, H; Djimde, M; Dorlo, TP; Erhart, A; González, R; Kabore, B; Kayentao, K; Keita, M; Macuacua, S; Menendez, C; Mens, P; Muhindo, HM; Piqueras, M; Sagara, I; Schallig, H; Sevene, E; Tinto, H; Traore, M; Tshiongo, JK; Vala, A, 2023) | 0.91 |
| Excerpt | Reference | Relevance |
|---|
| "To investigate the pharmacokinetic and pharmacodynamic properties of artemether and benflumetol in a fixed combination tablet (CGP 56697) and to offer an explanation for the lower than expected cure rate in a Thai clinical trial." | ( Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.
Ezzet, F; Karbwang, J; Mull, R, 1998) | 0.3 |
| " Parasite clearance time and 28 day cure rate were correlated with the derived pharmacokinetic parameters." | ( Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.
Ezzet, F; Karbwang, J; Mull, R, 1998) | 0.3 |
| "Using a population-based approach it was confirmed that the pharmacokinetic and pharmacodynamic properties of benflumetol and artemether differ markedly." | ( Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.
Ezzet, F; Karbwang, J; Mull, R, 1998) | 0.3 |
| " The pharmacokinetics of benflumetol were highly variable, with coefficients of variation in pharmacokinetic parameters ranging from 14." | ( Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria.
Farkad, E; Karbwang, J; Mull, R; Na-Bangchang, K; Tasanor, U; Thanavibul, A, 1999) | 0.3 |
| "To evaluate whether the potent CYP3A4 inhibitor ketoconazole has any influence on the pharmacokinetic and electrocardiographic parameters of the antimalarial co-artemether (artemether-lumefantrine) in healthy subjects." | ( Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects.
Carpenter, P; Lefèvre, G; McClean, M; Schmidli, H; Souppart, C; Stypinski, D, 2002) | 0.31 |
| "Lumefantrine pharmacokinetic profiles were obtained for 36 patients." | ( Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria.
Annerberg, A; Ashley, EA; Brockman, A; Hla, G; Hutagalung, R; Lindegårdh, N; McGready, R; Nosten, F; Proux, S; Singhasivanon, P; Singtoroj, T; Stepniewska, K; White, NJ; Wilahphaingern, J, 2007) | 0.34 |
| "Artemether and lumefantrine (AL), the active constituents of Coartem exhibit complementary pharmacokinetic profiles." | ( Understanding the pharmacokinetics of Coartem.
Djimdé, A; Lefèvre, G, 2009) | 0.35 |
| "The overall pharmacokinetic properties of artemether and dihydroartemisinin in healthy Pakistani subjects are comparable to healthy subjects and patients from other populations." | ( Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine.
Ali, S; Lindegardh, N; Najmi, MH; Tarning, J, 2010) | 0.36 |
| "Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions." | ( Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
Back, D; Byakika-Kibwika, P; de Vries, PJ; Hanpithakpong, W; Katabira, E; Khoo, S; Lamorde, M; Lindegardh, N; Mayanja-Kizza, H; Mayito, J; Merry, C; Nabukeera, L; Namakula, R; Ntale, M; Pakker, N; Ryan, M; Tarning, J, 2012) | 0.38 |
| " Clinical data from population pharmacokinetic and pharmacodynamic trials evaluating the impact of these drug interactions are urgently needed." | ( Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
Back, D; Byakika-Kibwika, P; de Vries, PJ; Hanpithakpong, W; Katabira, E; Khoo, S; Lamorde, M; Lindegardh, N; Mayanja-Kizza, H; Mayito, J; Merry, C; Nabukeera, L; Namakula, R; Ntale, M; Pakker, N; Ryan, M; Tarning, J, 2012) | 0.38 |
| "002) with EFV, but the LR half-life was unchanged." | ( Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.
Aweeka, FT; Dorsey, G; Havlir, D; Huang, L; Lizak, P; Marzan, F; Parikh, S; Rosenthal, PJ, 2012) | 0.38 |
| " Inter- and intra-individual variabilities in the pharmacokinetic parameters were assessed and the contribution of demographic and other covariates was quantified using a nonlinear mixed-effects modelling approach (NONMEM®)." | ( Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.
Ariey, F; Beck, HP; Buclin, T; Csajka, C; Decosterd, LA; Duong, S; Genton, B; Guidi, M; Kabanywanyi, AM; Mercier, T; Olliaro, P; Staehli Hodel, EM; Zanolari, B, 2013) | 0.39 |
| " From all the covariates tested, only body weight (for all antimalarials) and concomitant treatment (for artemether only) showed a significant influence on these drugs' pharmacokinetic profiles." | ( Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.
Ariey, F; Beck, HP; Buclin, T; Csajka, C; Decosterd, LA; Duong, S; Genton, B; Guidi, M; Kabanywanyi, AM; Mercier, T; Olliaro, P; Staehli Hodel, EM; Zanolari, B, 2013) | 0.39 |
| " Its efficacy during pregnancy has recently been challenged due to altered pharmacokinetic (PK) properties in this vulnerable group." | ( Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania.
Abdulla, S; Csajka, C; Decosterd, LA; Genton, B; Guidi, M; Mercier, T; Mosha, D; Mwingira, F, 2014) | 0.4 |
| " Overall, efficacy of these treatments appeared to be reduced, attributed to lower immunity and for some antimalarials altered pharmacokinetic profiles and lower drug concentrations." | ( A multi-center, open-label trial to compare the efficacy and pharmacokinetics of Artemether-Lumefantrine in children with severe acute malnutrition versus children without severe acute malnutrition: study protocol for the MAL-NUT study.
Barnes, KI; Baudin, E; Denoeud-Ndam, L; Dicko, A; Djimde, AA; Doumbo, OK; Etard, JF; Grandesso, F; Guindo, O; Lasry, E; Palma, PP; Parra, AM; Sagara, I; Stepniewska, K, 2015) | 0.42 |
| " To assess the pharmacokinetic profile of lumefantrine, a sparse sampling approach will be used with randomized allocation of sampling times (5 per child)." | ( A multi-center, open-label trial to compare the efficacy and pharmacokinetics of Artemether-Lumefantrine in children with severe acute malnutrition versus children without severe acute malnutrition: study protocol for the MAL-NUT study.
Barnes, KI; Baudin, E; Denoeud-Ndam, L; Dicko, A; Djimde, AA; Doumbo, OK; Etard, JF; Grandesso, F; Guindo, O; Lasry, E; Palma, PP; Parra, AM; Sagara, I; Stepniewska, K, 2015) | 0.42 |
| "This study will provide important information that is currently lacking on the effect of SAM on therapeutic efficacy and pharmacokinetic profile of artemether-lumefantrine." | ( A multi-center, open-label trial to compare the efficacy and pharmacokinetics of Artemether-Lumefantrine in children with severe acute malnutrition versus children without severe acute malnutrition: study protocol for the MAL-NUT study.
Barnes, KI; Baudin, E; Denoeud-Ndam, L; Dicko, A; Djimde, AA; Doumbo, OK; Etard, JF; Grandesso, F; Guindo, O; Lasry, E; Palma, PP; Parra, AM; Sagara, I; Stepniewska, K, 2015) | 0.42 |
| " Pharmacokinetic characterization of both drugs was performed after oral administration in rats." | ( Improved pharmacokinetic and pharmacodynamic attributes of artemether-lumefantrine-loaded solid SMEDDS for oral administration.
Bedi, N; Bhandari, S; Bhandari, V; Jaswal, S; Rana, V; Sehgal, R; Sood, J; Tiwary, AK, 2017) | 0.46 |
| " The aim of this study was to investigate the pharmacokinetic and pharmacodynamic properties of lumefantrine and the pharmacokinetic properties of its metabolite, desbutyl-lumefantrine, in order to inform optimal dosing regimens in all patient populations." | ( Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Ashley, EA; Ashton, M; Aweeka, F; Bakshi, R; Barnes, KI; Björkman, A; Borrmann, S; Checchi, F; Davis, TME; Deloron, P; Ezzet, F; Faucher, JF; Fogg, C; Friberg Hietala, S; Guerin, PJ; Hamed, K; Karbwang, J; Karunajeewa, H; Kloprogge, F; Kofoed, PE; Lefèvre, G; Mårtensson, A; Mayxay, M; McGready, R; Mwai, L; Newton, PN; Ngasala, B; Nosten, F; Parikh, S; Piola, P; Price, RN; Proux, S; Salman, S; Stepniewska, K; Tarning, J; Tékété, M; Ursing, J; van Vugt, M; White, NJ; Workman, L, 2018) | 0.48 |
| " The developed lumefantrine population pharmacokinetic model was used for dose optimisation through in silico simulations." | ( Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Ashley, EA; Ashton, M; Aweeka, F; Bakshi, R; Barnes, KI; Björkman, A; Borrmann, S; Checchi, F; Davis, TME; Deloron, P; Ezzet, F; Faucher, JF; Fogg, C; Friberg Hietala, S; Guerin, PJ; Hamed, K; Karbwang, J; Karunajeewa, H; Kloprogge, F; Kofoed, PE; Lefèvre, G; Mårtensson, A; Mayxay, M; McGready, R; Mwai, L; Newton, PN; Ngasala, B; Nosten, F; Parikh, S; Piola, P; Price, RN; Proux, S; Salman, S; Stepniewska, K; Tarning, J; Tékété, M; Ursing, J; van Vugt, M; White, NJ; Workman, L, 2018) | 0.48 |
| " A population pharmacokinetic meta-analysis was conducted using individual participant data from 10 studies with 6,100 lumefantrine concentrations from 793 nonpregnant adult participants (41% HIV-malaria-coinfected, 36% malaria-infected, 20% HIV-infected, and 3% healthy volunteers)." | ( An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment.
Aweeka, FT; Barnes, KI; Byakika-Kibwika, P; Bygbjerg, IC; Chijioke-Nwauche, I; Denti, P; Francis, J; Hoglund, RM; Khoo, SH; Kredo, T; Lamorde, M; Lemnge, MM; Merry, C; Nyagonde, N; Parikh, S; Scarsi, KK; Sutherland, CJ; Tarning, J; Vestergaard, LS; Walimbwa, SI; Workman, L, 2020) | 0.56 |
| " Pharmacokinetic parameters were obtained from intensive plasma concentration-time data." | ( Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz.
Adeagbo, BA; Adegbola, AJ; Bolaji, OO; Bolarinwa, RA; Olagunju, AE; Owen, A; Rana, A; Siccardi, M, 2020) | 0.56 |
| " Blood samples were collected for parasite detection (by microscopy and PCR), molecular genotyping and pharmacokinetic analyses." | ( Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tan
Barnes, R; Björkman, A; Kitabi, EN; Mårtensson, A; Mhamilawa, LE; Mmbando, BP; Morris, U; Ngasala, B; Soe, AP, 2020) | 0.56 |
| "We developed a population pharmacokinetic model of dolutegravir with data from 26 healthy volunteers in two Phase 2 studies with a total of 403 dolutegravir plasma concentrations at steady state." | ( Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine.
Denti, P; Kawuma, AN; Khoo, S; Lamorde, M; Pillai, GC; Walimbwa, SI; Wasmann, RE, 2021) | 0.62 |
| " However, interaction of both drugs, with Cytochrome P 3A4 (CYP 3A4) isoenzyme, may spawn clinically significant pharmacokinetic interactions." | ( Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital, South-Western Nigeria.
Abideen, G; Adewumi, OO; Agbaje, EO; Akanmu, AS; Akinleye, MO; Akinyede, A; Busari, AA; Hassan, OO; Kadri, MR; Oreagba, IA; Usman, SO, 2021) | 0.62 |
| " The concentration of lumefantrine in each sample was quantified with high-performance liquid chromatography (HPLC) and used to determine its pharmacokinetic parameters which were compared between the test and control groups." | ( Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital, South-Western Nigeria.
Abideen, G; Adewumi, OO; Agbaje, EO; Akanmu, AS; Akinleye, MO; Akinyede, A; Busari, AA; Hassan, OO; Kadri, MR; Oreagba, IA; Usman, SO, 2021) | 0.62 |
| "The aim of this study was to assess the pharmacokinetic properties of artemether, lumefantrine and their active metabolites in Plasmodium knowlesi malaria." | ( The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria.
Davis, TME; Davis, WA; Hii, KC; Page-Sharp, M; Salman, S; Singh, B; Sugiarto, SR, 2022) | 0.72 |
| " Multi-compartmental population pharmacokinetic models were developed using plasma with or without DBS drug concentrations." | ( The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria.
Davis, TME; Davis, WA; Hii, KC; Page-Sharp, M; Salman, S; Singh, B; Sugiarto, SR, 2022) | 0.72 |
| " DBS lumefantrine concentrations can be used in pharmacokinetic studies but DBS technology is currently unreliable for the other analytes." | ( The pharmacokinetic properties of artemether and lumefantrine in Malaysian patients with Plasmodium knowlesi malaria.
Davis, TME; Davis, WA; Hii, KC; Page-Sharp, M; Salman, S; Singh, B; Sugiarto, SR, 2022) | 0.72 |
| " The aim of this study was to investigate the pharmacokinetic properties of artemether, lumefantrine and their active metabolites dihydroartemisinin and desbutyl-lumefantrine in 16 normal-weight, overweight and obese healthy male volunteers [body mass index (BMI) categories ≤25 kg/m², >25-≤30 kg/m² and >30 kg/m², respectively; absolute range 19." | ( Pharmacokinetic properties of the antimalarial combination therapy artemether-lumefantrine in normal-weight, overweight and obese healthy male adults.
Davis, TME; Davis, WA; Drinkwater, JJ; Page-Sharp, M; Salman, S; Sugiarto, SR, 2022) | 0.72 |
| Excerpt | Reference | Relevance |
|---|
| " The variability in bioavailability of artemether and dihydroartemisinin was large both between doses and between patients, but was less pronounced for benflumetol." | ( Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.
Ezzet, F; Karbwang, J; Mull, R, 1998) | 0.3 |
| " Lumefantrine bioavailability is enhanced by food, particularly fat." | ( The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence.
Abdulla, S; Falade, CO; Kokwaro, G; Mulure, N; Ndong, A; Nwaiwu, O; Ogutu, B; Premji, ZG; Sagara, I, 2008) | 0.35 |
| " These failures are believed to be a consequence of poor bioavailability of the lumefantrine component when ingested without fatty food." | ( First case of treatment failure of artemether-lumefantrine in a Japanese traveler with imported falciparum malaria.
Kano, S; Kato, Y; Kudo, K; Mizuno, Y, 2009) | 0.35 |
| " Food intake significantly enhances the bioavailability of both artemether and lumefantrine, an effect which is more apparent for the highly lipophilic lumefantrine." | ( Understanding the pharmacokinetics of Coartem.
Djimdé, A; Lefèvre, G, 2009) | 0.35 |
| " Therefore, we evaluated the effect of food intake on oral lumefantrine bioavailability in African children with malaria." | ( The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.
Björkman, A; Borrmann, S; D'Alessandro, U; Djimdé, A; González, R; Hamel, M; Juma, E; Kern, SE; Lefèvre, G; Machevo, S; Marrast, AC; Mårtensson, A; Ogutu, B; Peshu, J; Sallas, WM, 2010) | 0.36 |
| " Similarly, consumption of milk (the most common meal) increased model-estimated lumefantrine bioavailability by 57% (90% CI: 29-96%) with crushed tablets and 65% (90% CI: 28-109%) with dispersible tablets compared to no food." | ( The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria.
Björkman, A; Borrmann, S; D'Alessandro, U; Djimdé, A; González, R; Hamel, M; Juma, E; Kern, SE; Lefèvre, G; Machevo, S; Marrast, AC; Mårtensson, A; Ogutu, B; Peshu, J; Sallas, WM, 2010) | 0.36 |
| " During early development of this new formulation, two studies were performed in healthy subjects, one to evaluate the palatability of three flavours of A-L, and a second one to compare the bioavailability of active principles between the dispersible tablet and the tablet (administered crushed and intact)." | ( Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects.
Abdulla, S; Amuri, B; Fitoussi, S; Kabanywanyi, AM; Kaiser, G; Lefèvre, G; Nuortti, M; Pascoe, S; Reynolds, C; Séchaud, R; Ubben, D; Yeh, CM, 2010) | 0.36 |
| " The objectives were to compare the bioavailability of artemether, dihydroartemisinin (DHA) and lumefantrine between the dispersible tablet and the tablet administered crushed (primary objective) and intact (secondary objective)." | ( Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects.
Abdulla, S; Amuri, B; Fitoussi, S; Kabanywanyi, AM; Kaiser, G; Lefèvre, G; Nuortti, M; Pascoe, S; Reynolds, C; Séchaud, R; Ubben, D; Yeh, CM, 2010) | 0.36 |
| " This study explored the effects of cheap local food in Uganda on oral bioavailability of lumefantrine relative to milk." | ( Comparable lumefantrine oral bioavailability when co-administered with oil-fortified maize porridge or milk in healthy volunteers.
Beck, O; Gustafsson, LL; Hellgren, U; Jerling, M; Mahindi, M; Mwebaza, N; Ntale, M; Obua, C; Waako, P, 2013) | 0.39 |
| " The relative bioavailability of lumefantrine and its metabolism rate into desmethyl-lumefantrine were, respectively, 34% lower and 78% higher in pregnant women than in nonpregnant patients." | ( Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania.
Abdulla, S; Csajka, C; Decosterd, LA; Genton, B; Guidi, M; Mercier, T; Mosha, D; Mwingira, F, 2014) | 0.4 |
| " Soluplus(®) (polyethyleneglycol-polyvinyl caprolactam-polyvinyl acetate grafted copolymer) was used as primary carrier matrices via hot-melt extrusion processing to improve solubility profile and the oral bioavailability of the combination." | ( Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): Evaluating amorphous state and in vivo performance.
Amin, P; Dhamecha, D; Fule, R; Khale, A; Maniruzzaman, M, 2015) | 0.42 |
| " In an attempt to enhance the bioavailability of lumefantrine, new solid dispersion formulations (SDF) were developed, and the pharmacokinetics of two SDF variants were assessed in a randomized, open-label, sequential two-part study in healthy volunteers." | ( Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers.
Chen, L; Jain, JP; Kalluri, S; Koradia, V; Kota, J; Leong, FJ; Stein, DS; Sunkara, G; Wolf, MC, 2017) | 0.46 |
| "Artemether and lumefantrine display low aqueous solubility leading to poor release profile; hence the need for the use of lipid-based systems to improve their oral bioavailability so as to improve their therapeutic efficacy." | ( Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration.
Akpa, PA; Attama, AA; Echezona, AC; Ezeibe, EN; Kenechukwu, FC; Momoh, MA; Ugwu, CN; Ugwuoke, JA, 2020) | 0.56 |
| "The objective of this work was to utilize potentials of nanostructured lipid carriers (NLCs) for improvement of the oral bioavailability of artemether and lumefantrine combination and to evaluate its efficacy in the treatment of malaria." | ( Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration.
Akpa, PA; Attama, AA; Echezona, AC; Ezeibe, EN; Kenechukwu, FC; Momoh, MA; Ugwu, CN; Ugwuoke, JA, 2020) | 0.56 |
| "This study has shown the potential of caprol-based NLCs for significant improvement in oral bioavailability and hence antimalarial activity of poorly soluble artemether and lumefantrine." | ( Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration.
Akpa, PA; Attama, AA; Echezona, AC; Ezeibe, EN; Kenechukwu, FC; Momoh, MA; Ugwu, CN; Ugwuoke, JA, 2020) | 0.56 |
| " Typically, ART and LUM are delivered orally in the form of a combined tablet, however, the appropriateness of this route of administration for these drugs is questionable due to the poor absorption and therefore bioavailability observed unless administered alongside lipid-rich foods." | ( Novel transdermal bioadhesive surfactant-based system for release and solubility improvement of antimalarial drugs artemether-lumefantrine.
Akira D'Ávila, M; Brisibe, A; Ceccheto Figueiredo, M; Chorilli, M; Dávila, JL; Donnelly, RF; Foglio, MA; Fonseca-Santos, B; McCrudden, MTC; McKenna, PE; Paredes, AJ; Tangerina, MMP; Vilegas, W; Volpe-Zanutto, F, 2021) | 0.62 |
| Excerpt | Relevance | Reference |
|---|
| " CGP 56697 is an effective, well-tolerated treatment for uncomplicated falciparum malaria but for this dosing regimen the recrudescence rate is unacceptablyhigh (18%)." | ( The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France.
Barette, S; Bernard, J; Bouchaud, O; Danis, M; Delmont, J; Gathmann, I; Gras, C; Malvy, D; Mull, R; Touze, JE; van Agtmael, M, 1999) | 0.3 |
| "Electrocardiograms (ECGs) were recorded before dosing and repeatedly thereafter." | ( Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers.
Bindschedler, M; Ezzet, F; Lefèvre, G; Meyer, I; Schaeffer, N; Thomsen, MS, 2000) | 0.31 |
| " Electrocardiograms (ECGs) were recorded from 48 hours before dosing until 48 hours thereafter." | ( Comparison of the cardiac effects of the antimalarials co-artemether and halofantrine in healthy participants.
Bindschedler, M; Degen, P; Lefèvre, G; Sioufi, A, 2002) | 0.31 |
| " The aim of this study was to describe the dose-response relationship between coadministration of fat and relative lumefantrine bioavailability, in order to determine the minimum amount of fat necessary to optimize absorption." | ( How much fat is necessary to optimize lumefantrine oral bioavailability?
Annerberg, A; Ashley, EA; Brockman, A; Kham, A; Lindegårdh, N; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ, 2007) | 0.34 |
| "A dose-response relationship was demonstrated between the volume of soya milk administered and lumefantrine bioavailability." | ( How much fat is necessary to optimize lumefantrine oral bioavailability?
Annerberg, A; Ashley, EA; Brockman, A; Kham, A; Lindegårdh, N; Nosten, F; Singhasivanon, P; Stepniewska, K; White, NJ, 2007) | 0.34 |
| " Health facility and health worker readiness improved from 2004 to 2006: availability of artemether-lumefantrine from 51% (48/94) to 60% (62/104), presence of artemether-lumefantrine dosage wall charts from 20% (19/94) to 75% (78/104), possession of guidelines from 58% (60/103) to 92% (124/135), and provision of in-service training from 25% (26/103) to 41% (55/135)." | ( Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study.
Chanda, P; Hamer, DH; Ndhlovu, M; Simon, JL; Sipilanyambe, N; Snow, RW; Zurovac, D, 2007) | 0.34 |
| " Taking an appropriate dosage and providing patients with proper instructions on taking the drug concurrently with fatty food are required for effective treatment with artemether-lumefantrine." | ( First case of treatment failure of artemether-lumefantrine in a Japanese traveler with imported falciparum malaria.
Kano, S; Kato, Y; Kudo, K; Mizuno, Y, 2009) | 0.35 |
| " These trials have involved more than 3,500 patients (including over 2,000 children), and led to identification of a six-dose, three-day regimen as the optimal dosing strategy for AL in uncomplicated falciparum malaria." | ( Coartem: the journey to the clinic.
Premji, ZG, 2009) | 0.35 |
| " The pharmacokinetics of artemether or lumefantrine are similar in children, when dosed according to their body weight, compared with adults." | ( Understanding the pharmacokinetics of Coartem.
Djimdé, A; Lefèvre, G, 2009) | 0.35 |
| " HWs almost always dosed AL correctly and gave accurate dosing instructions to patients; however, other aspects of counseling needed improvement." | ( Quality of malaria case management at outpatient health facilities in Angola.
de León, GF; Mihigo, J; Miller, NP; Rowe, AK; Santelli, AC; Van-Dúnem, P, 2009) | 0.35 |
| " Dosage was incorrect in 26." | ( [Management of malaria in Benin: evaluation of the practices of healthcare professionals following the introduction of artemisinin derivatives].
Abdillahi, A; Kinde-Gazard, D; Massougbodji, A; Nahum, A; Ogouyemi-Hounto, A, 2009) | 0.35 |
| " The dosing pictogram and clustering of tablets within the blister packs was considered helpful by 91." | ( Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania.
Genton, B; Kabanywanyi, AM; Kasim, P; King'eng'ena, S; Lengeler, C; Mulure, N; Schlienger, R, 2010) | 0.36 |
| "Factors contributing to adherence were likely to be helpful packaging, pictorial dosing instructions and patients' conviction that AL is effective." | ( Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania.
Genton, B; Kabanywanyi, AM; Kasim, P; King'eng'ena, S; Lengeler, C; Mulure, N; Schlienger, R, 2010) | 0.36 |
| "Adherence to the dosing regimen and timing of AL administration was very good." | ( Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania.
Genton, B; Kabanywanyi, AM; Kasim, P; King'eng'ena, S; Lengeler, C; Mulure, N; Schlienger, R, 2010) | 0.36 |
| " Mothers' knowledge and reporting of ALu's dosage was, in many cases, inconsistent with the recommended dosage schedule for children." | ( Community response to artemisinin-based combination therapy for childhood malaria: a case study from Dar es Salaam, Tanzania.
Kamat, VR; Nyato, DJ, 2010) | 0.36 |
| "To compare, in a phase IV trial, the efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) dosed at 300 and 600 mg of amodiaquine per tablet to artemether-lumefantrine (Coartem) for the treatment of Plasmodium falciparum uncomplicated malaria in Ivory Coast and Senegal." | ( Efficacy and tolerability of artesunate-amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast.
Djoman, K; Faye, B; Gaye, O; Ndiaye, JL; Ndiaye, PS; Offianan, AT; Penali, L; Sylla, K; Tine, RC; Touré, W, 2010) | 0.36 |
| " After excluding genetic host factors by genotyping potentially relevant cytochrome P450 loci, the high number of treatment failures in our study is best explained by poor adherence to complex dosing regimens in combination with insufficient fat supplementation, which are both crucial parameters for the outcome of Coartem treatment." | ( Treatment with coartem (artemether-lumefantrine) in Papua New Guinea.
DaRe, JT; Felger, I; Kiniboro, B; Lin, E; Mehlotra, RK; Mueller, I; Schoepflin, S; Zimmerman, PA, 2010) | 0.36 |
| " The system covered stocks of the four different dosage packs of artemether-lumefantrine (AL) and quinine injectable." | ( SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology.
Barrington, J; Kungulwe, S; Mwafongo, W; Ward, P; Wereko-Brobby, O, 2010) | 0.36 |
| " Because of concerns about the complex dosing schedule, we assessed patient adherence to AL 2 years after routine implementation." | ( Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi.
Ali, D; Filler, SJ; Jafali, J; Kachur, SP; Luka, M; Mace, KE; Mathanga, DP; Mwandama, D; Sande, J; Skarbinski, J, 2011) | 0.37 |
| "Overall, adherence to AL was found to be low in both Garissa and Bunyala districts, with patient knowledge of the AL dosing regimen found to be the strongest predictor of adherence." | ( Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya.
Allan, R; Cowley, A; Hoibak, S; Juma, E; Lawford, H; Munga, S; O'Reilly, L; Snow, RW; Vulule, J; Zurovac, D, 2011) | 0.37 |
| " The age-based dosage schedule and lack of adherence to ALu treatment guidelines by health facility staff may explain both the huge variability in observed lumefantrine concentrations and the lack of difference in concentrations between the two groups." | ( Adherence to artemether/lumefantrine treatment in children under real-life situations in rural Tanzania.
Gustafsson, LL; Kakoko, D; Mahindi, M; Petzold, M; Premji, Z; Simba, DO; Tomson, G, 2012) | 0.38 |
| " In the three AL body weight dosing groups (5 to < 15 kg, 15 to < 25 kg and 25 to < 35 kg), 80% of patients were aged 10-50 months, 46-100 months and 90-147 months, respectively." | ( Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges.
Bashraheil, M; Bassat, Q; González, R; Kipkeu, C; Lefèvre, G; Lyimo, J; Machevo, S; Maiga, H; Mårtensson, A; Menéndez, C; Nahum, A; Nwaiwu, O; Ogutu, B; Ouma, P; Ubben, D; Walter, V, 2011) | 0.37 |
| "Efficacy of AL in uncomplicated falciparum malaria is similar across body weight dosing groups as currently recommended in the label with no clinically relevant differences in safety or tolerability." | ( Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges.
Bashraheil, M; Bassat, Q; González, R; Kipkeu, C; Lefèvre, G; Lyimo, J; Machevo, S; Maiga, H; Mårtensson, A; Menéndez, C; Nahum, A; Nwaiwu, O; Ogutu, B; Ouma, P; Ubben, D; Walter, V, 2011) | 0.37 |
| " Although adherence to artemether-lumefantrine has been described as a potential problem due to the complicated dosing schedule, studies have described clinical cure rates similar to those of other antimalarials." | ( Artemether-lumefantrine: an option for malaria.
King, ST; Robinson, J; Stover, KR, 2012) | 0.38 |
| " However, the observed modest changes probably do not warrant dosage adjustment during co-administration of AL with EFV." | ( Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.
Aweeka, FT; Dorsey, G; Havlir, D; Huang, L; Lizak, P; Marzan, F; Parikh, S; Rosenthal, PJ, 2012) | 0.38 |
| "Mechanistic within-host models relating blood anti-malarial drug concentrations with the parasite-time profile help in assessing dosing schedules and partner drugs for new anti-malarial treatments." | ( Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development.
Charman, SA; Gamo-Benito, J; Humberstone, A; Jamsen, KM; McCaw, J; Moehrle, J; Price, RN; Simpson, JA; Smith, K; Zaloumis, S, 2012) | 0.38 |
| " Patients were randomized (2:1) to pyronaridine-artesunate granules (60/20 mg) once daily or artemether-lumefantrine crushed tablets (20/120 mg) twice daily, both dosed by bodyweight, orally (liquid suspension) for three days." | ( Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial.
Bhatt, KM; Borghini-Fuhrer, I; Bustos, MD; de Salazar, PM; Doumbo, OK; Duparc, S; Fleckenstein, L; Kayentao, K; Kimani, J; Kokolomami, JH; Offianan, AT; Ouédraogo, A; Pénali, LK; Quicho, F; Ramharter, M; Shin, CS; Tiono, AB; Tshefu, AK, 2012) | 0.38 |
| " The current study evaluated providers' knowledge and practices of treatment policy and dosing regimens with AL and quinine in the public, private and not-for-profit drug outlets." | ( Provider knowledge of treatment policy and dosing regimen with artemether-lumefantrine and quinine in malaria-endemic areas of western Kenya.
Abong'o, BO; Ombaka, JH; Onyango, RO; Ouma, C; Watsierah, CA, 2012) | 0.38 |
| " Information on provider in-service training, knowledge (qualification, treatment policy, dosing regimen, recently banned anti-malarials) and on practices (request for written prescription, prescription of AL, selling partial packs and advice given to patients after prescription), was collected." | ( Provider knowledge of treatment policy and dosing regimen with artemether-lumefantrine and quinine in malaria-endemic areas of western Kenya.
Abong'o, BO; Ombaka, JH; Onyango, RO; Ouma, C; Watsierah, CA, 2012) | 0.38 |
| "Public-sector providers have higher knowledge on treatment policy and dosing regimen on recommended anti-malarials." | ( Provider knowledge of treatment policy and dosing regimen with artemether-lumefantrine and quinine in malaria-endemic areas of western Kenya.
Abong'o, BO; Ombaka, JH; Onyango, RO; Ouma, C; Watsierah, CA, 2012) | 0.38 |
| " Fatty diet requirements for optimal absorption, pregnancy-induced changes in pharmacokinetics, pregnancy-related anorexia and food taboos, and emerging reduced parasite sensitivity to artemisinin, challenges optimal artemether-lumefantrine dosing and efficacy during pregnancy." | ( Use of artemether-lumefantrine to treat malaria during pregnancy: what do we know and need to know?
Adam, I; Mutabingwa, TK, 2013) | 0.39 |
| " Peak concentrations (Cmax ) and area under concentration-time curve restricted to 48 hr after single dosing (AUC(0-48) ) were selected for relative bioavailability evaluations using confidence interval approach for average bioequivalence." | ( Comparable lumefantrine oral bioavailability when co-administered with oil-fortified maize porridge or milk in healthy volunteers.
Beck, O; Gustafsson, LL; Hellgren, U; Jerling, M; Mahindi, M; Mwebaza, N; Ntale, M; Obua, C; Waako, P, 2013) | 0.39 |
| " Dosing on body weight appears justified." | ( Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.
Ariey, F; Beck, HP; Buclin, T; Csajka, C; Decosterd, LA; Duong, S; Genton, B; Guidi, M; Kabanywanyi, AM; Mercier, T; Olliaro, P; Staehli Hodel, EM; Zanolari, B, 2013) | 0.39 |
| " We assessed the dose-response association of single-dose primaquine for gametocyte clearance and for safety in P falciparum malaria." | ( Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial.
Bousema, T; Bradley, J; Drakeley, C; Eziefula, AC; Gabagaya, G; Grignard, L; Kamya, M; Lanke, KH; Mpimbaza, A; Nsobya, S; Owaraganise, A; Staedke, SG; Wanzira, H; Webb, EL; White, NJ; Yeung, S, 2014) | 0.4 |
| "Use of artemisinin-based combination therapy (ACT), such as artemether-lumefantrine (AL), requires a strict dosing schedule that follows the drugs' pharmacokinetic properties." | ( Correct dosing of artemether-lumefantrine for management of uncomplicated malaria in rural Tanzania: do facility and patient characteristics matter?
Amuri, B; de Savigny, D; Kachur, SP; Kajungu, D; Khatib, RA; Kuepfer, I; Masanja, IM; Selemani, M; Skarbinski, J, 2013) | 0.39 |
| " The outcome was correct dosing of AL based on age and weight." | ( Correct dosing of artemether-lumefantrine for management of uncomplicated malaria in rural Tanzania: do facility and patient characteristics matter?
Amuri, B; de Savigny, D; Kachur, SP; Kajungu, D; Khatib, RA; Kuepfer, I; Masanja, IM; Selemani, M; Skarbinski, J, 2013) | 0.39 |
| "7% of patients received correct dosing by weight alone and 78." | ( Correct dosing of artemether-lumefantrine for management of uncomplicated malaria in rural Tanzania: do facility and patient characteristics matter?
Amuri, B; de Savigny, D; Kachur, SP; Kajungu, D; Khatib, RA; Kuepfer, I; Masanja, IM; Selemani, M; Skarbinski, J, 2013) | 0.39 |
| "Although malaria treatment guidelines indicate AL dosing can be prescribed based on age or weight of the patient, findings from this study show that patients within the middle age and weight dosing bands were least likely to receive a correct dose by either measure." | ( Correct dosing of artemether-lumefantrine for management of uncomplicated malaria in rural Tanzania: do facility and patient characteristics matter?
Amuri, B; de Savigny, D; Kachur, SP; Kajungu, D; Khatib, RA; Kuepfer, I; Masanja, IM; Selemani, M; Skarbinski, J, 2013) | 0.39 |
| " The development of appropriate pragmatic dosing regimens for low-resource settings or community-based use is not formally regulated, even though these may alter factors which can substantially affect individual patient and population level outcome, such as drug exposure, patient adherence and the spread of drug resistance and can affect a drug's reputation and its eventual therapeutic lifespan." | ( Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.
Hastings, IM; Hayes, DJ; Hodel, EM; Kay, K; Terlouw, DJ, 2014) | 0.4 |
| "An in silico pharmacological model of anti-malarial drug treatment with the pharmacokinetic/pharmacodynamic profiles of artemether-lumefantrine (AM-LF, Coartem®) and dihydroartemisinin-piperaquine (DHA-PPQ, Eurartesim®) was constructed to assess the potential impact of programmatic factors, including regionally optimized, age-based dosing regimens, poor patient adherence, food effects and drug resistance on treatment outcome at population level, and compared both drugs' susceptibility to these factors." | ( Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.
Hastings, IM; Hayes, DJ; Hodel, EM; Kay, K; Terlouw, DJ, 2014) | 0.4 |
| "Compared with DHA-PPQ, therapeutic effectiveness of AM-LF seems more robust to factors affecting drug exposure, such as age- instead of weight-based dosing or poor adherence." | ( Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.
Hastings, IM; Hayes, DJ; Hodel, EM; Kay, K; Terlouw, DJ, 2014) | 0.4 |
| " These factors determine the adherence to the dosing schedules during the treatment course and thus the evaluation of the subsidy policy, its implementation and role in malaria burden in this region is compulsory." | ( Access to artemisinin-based combination therapy (ACT) and quinine in malaria holoendemic regions of western Kenya.
Ouma, C; Watsierah, CA, 2014) | 0.4 |
| " This result relies on the assumption that compliance to treatment with DhP is higher than that with AL due to its relatively simple once-a-day dosage regimen." | ( Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania.
Mori, AT; Ngalesoni, F; Norheim, OF; Robberstad, B, 2014) | 0.4 |
| "Adherence to anti-malarial dosing schedules is essential to ensure effective treatment." | ( Perceptions and utilization of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine in young children in the Chikhwawa District of Malawi: a mixed methods study.
Ewing, VL; Kapinda, A; Lalloo, DG; Pace, C; Richards, E; Terlouw, DJ; Tolhurst, R, 2015) | 0.42 |
| " While the sweet taste of dispersible AL may have reduced conflict between the child and caregiver, sub-optimal dosing due to medication loss remained a problem and overall adherence was greater among those receiving DHA-PPQ, which requires fewer doses." | ( Perceptions and utilization of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine in young children in the Chikhwawa District of Malawi: a mixed methods study.
Ewing, VL; Kapinda, A; Lalloo, DG; Pace, C; Richards, E; Terlouw, DJ; Tolhurst, R, 2015) | 0.42 |
| " We investigated the effect of dosing strategy on efficacy in a pooled analysis from trials done in a wide range of malaria-endemic settings." | ( The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data.
, 2015) | 0.42 |
| " Hence, dosing recommendations cannot be made in infants <5 kg as implications for toxicity are unknown." | ( Increased systemic exposures of artemether and dihydroartemisinin in infants under 5 kg with uncomplicated Plasmodium falciparum malaria treated with artemether-lumefantrine (Coartem®).
Alao, MJ; Cousin, M; Duparc, S; Hamed, K; Jain, JP; Lefèvre, G; Lingani, M; Meremikwu, M; Ogutu, B; Ouedraogo, A; Tinto, H; Tiono, AB; Tshefu, A, 2015) | 0.42 |
| " Malaria patients rarely contain more than 10(12) parasites, while the standard dosing regimens allow approximately 1 in 10(10) parasites to survive artemisinin treatment." | ( Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness.
Hastings, IM; Hodel, EM; Kay, K, 2015) | 0.42 |
| " These results support additional studies of artemisinin dosing and duration in CMV infection." | ( Effect of artemether-lumefantrine (Coartem) on cytomegalovirus urine viral load during and following treatment for malaria in children.
Arav-Boger, R; Barger-Kamate, B; Djimde, A; Forman, M; Haidara, AS; Maiga, H; Sangare, CO; Vaidya, D, 2016) | 0.43 |
| " Using a combination of CD3+, with either the Minilab or TruScan, to screen for medicine quality will allow for complete examination of both the dosage units and the packaging to decide whether it is authentic or counterfeit." | ( Assessment of the effectiveness of the CD3+ tool to detect counterfeit and substandard anti-malarials.
Batson, JS; Bempong, DK; Lukulay, PH; Ranieri, N; Satzger, RD; Verbois, L, 2016) | 0.43 |
| " For those on EFV, close clinical follow-up for recurrent malaria following artemether-lumefantrine treatment, along with the study of modified dosing regimens that provide higher exposure, is warranted." | ( Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.
Achan, J; Aweeka, FT; Gao, Q; Huang, L; Kajubi, R; Kakuru, A; Kiconco, S; Li, F; Mwebaza, N; Parikh, S; Ssebuliba, J; Were, M, 2016) | 0.43 |
| " Our report warrants the need to establish optimal dosing of AL in adults and to alert clinicians about the importance of informing patients regarding the risk of parasites reappearing weeks after AL treatment." | ( High Rate of Treatment Failures in Nonimmune Travelers Treated With Artemether-Lumefantrine for Uncomplicated Plasmodium falciparum Malaria in Sweden: Retrospective Comparative Analysis of Effectiveness and Case Series.
Asghar, M; Färnert, A; Gustafsson, LL; Hellgren, U; Homann, MV; Jovel, I; Pohanka, A; Sondén, K; Vieira da Silva, A; Wyss, K, 2017) | 0.46 |
| "5 mg can make dosing convenient in children." | ( Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Rando
Anvikar, AR; Behra, N; Das, RR; Gaye, O; Jalali, RK; Maheshwar, AV; Mishra, P; Mwapasa, V; Nasa, A; Roy, A; Sagara, I; Sharma, P; Sharma, SK; Thompson, R; Toure, OA; Tshefu, AK; Valecha, N, 2017) | 0.46 |
| " All treatments were once-daily or twice-daily tablets or granules given orally and dosed by bodyweight over 3 days at the study centre." | ( Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
, 2018) | 0.48 |
| " falciparum malaria were randomly assigned in a 1:1 ratio to orally receive pyronaridine-artesunate or artemether-lumefantrine, dosed according to bodyweight, for 3 days." | ( Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial.
Choy, F; Makio, N; Mens, P; Okach, S; Omweri, G; Osoti, V; Roth, JM; Sawa, P; Schallig, HDFH, 2018) | 0.48 |
| " The aim of this study was to investigate the pharmacokinetic and pharmacodynamic properties of lumefantrine and the pharmacokinetic properties of its metabolite, desbutyl-lumefantrine, in order to inform optimal dosing regimens in all patient populations." | ( Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Ashley, EA; Ashton, M; Aweeka, F; Bakshi, R; Barnes, KI; Björkman, A; Borrmann, S; Checchi, F; Davis, TME; Deloron, P; Ezzet, F; Faucher, JF; Fogg, C; Friberg Hietala, S; Guerin, PJ; Hamed, K; Karbwang, J; Karunajeewa, H; Kloprogge, F; Kofoed, PE; Lefèvre, G; Mårtensson, A; Mayxay, M; McGready, R; Mwai, L; Newton, PN; Ngasala, B; Nosten, F; Parikh, S; Piola, P; Price, RN; Proux, S; Salman, S; Stepniewska, K; Tarning, J; Tékété, M; Ursing, J; van Vugt, M; White, NJ; Workman, L, 2018) | 0.48 |
| " Simulations using the lumefantrine pharmacokinetic model suggest that, in young children and pregnant women beyond the first trimester, lengthening the dose regimen (twice daily for 5 days) and, to a lesser extent, intensifying the frequency of dosing (3 times daily for 3 days) would be more efficacious than using higher individual doses in the current standard treatment regimen (twice daily for 3 days)." | ( Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Ashley, EA; Ashton, M; Aweeka, F; Bakshi, R; Barnes, KI; Björkman, A; Borrmann, S; Checchi, F; Davis, TME; Deloron, P; Ezzet, F; Faucher, JF; Fogg, C; Friberg Hietala, S; Guerin, PJ; Hamed, K; Karbwang, J; Karunajeewa, H; Kloprogge, F; Kofoed, PE; Lefèvre, G; Mårtensson, A; Mayxay, M; McGready, R; Mwai, L; Newton, PN; Ngasala, B; Nosten, F; Parikh, S; Piola, P; Price, RN; Proux, S; Salman, S; Stepniewska, K; Tarning, J; Tékété, M; Ursing, J; van Vugt, M; White, NJ; Workman, L, 2018) | 0.48 |
| "Our findings suggest that revised AL dosing regimens for young children and pregnant women would improve drug exposure but would require longer or more complex schedules." | ( Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
Ashley, EA; Ashton, M; Aweeka, F; Bakshi, R; Barnes, KI; Björkman, A; Borrmann, S; Checchi, F; Davis, TME; Deloron, P; Ezzet, F; Faucher, JF; Fogg, C; Friberg Hietala, S; Guerin, PJ; Hamed, K; Karbwang, J; Karunajeewa, H; Kloprogge, F; Kofoed, PE; Lefèvre, G; Mårtensson, A; Mayxay, M; McGready, R; Mwai, L; Newton, PN; Ngasala, B; Nosten, F; Parikh, S; Piola, P; Price, RN; Proux, S; Salman, S; Stepniewska, K; Tarning, J; Tékété, M; Ursing, J; van Vugt, M; White, NJ; Workman, L, 2018) | 0.48 |
| " This study used three screening methods and one confirmatory method for the quality assessment of 25 batches of artemether/lumefantrine dosage forms from the Ghanaian market to test that combined screening methods only can rapidly detect substandard and/or falsified medicines in areas where confirmatory methods may not be available." | ( Usefulness of combined screening methods for rapid detection of falsified and/or substandard medicines in the absence of a confirmatory method.
Amartey, SNA; Dzidonu, A; Larbi, MA; Nettey, H; Nti, G; Nyarko, AK; Opuni, KF; Owusu, NA; Owusu-Danso, P, 2019) | 0.51 |
| " These data suggest that malaria and HIV coinfected pregnant women may require adjustments in AL dosage or treatment duration to achieve exposure comparable with HIV-uninfected pregnant women." | ( Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Aweeka, F; Huang, L; Hughes, E; Kajubi, R; Mwebaza, N; Mwima, MW; Nguyen, V; Nyunt, MM; Orukan, F; Parikh, S, 2020) | 0.56 |
| " Nineteen percent of HCPs thought that dihydroartemisinin/piperaquine gave the most satisfactory patient treatment outcomes, while 80% HCPs thought that artemether/lumefantrine gave the least satisfactory patient treatment outcomes, possibly due to dosing schedule and pill burden." | ( Healthcare professionals' perspective can guide post-marketing surveillance of artemisinin-based combination therapy in Uganda.
D'Hoore, W; Kiguba, R; Kirabira, E; Manirakiza, L; Mukonzo, J; Nabirye, L; Ndagije, HB; Olsson, S; Speybroeck, N; Spinewine, A; Sserwanga, A, 2020) | 0.56 |
| " This warrants further investigations of other drug-drug interactions for optimising dosing in genetically defined subgroups, particularly during drug development." | ( Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz.
Adeagbo, BA; Adegbola, AJ; Bolaji, OO; Bolarinwa, RA; Olagunju, AE; Owen, A; Rana, A; Siccardi, M, 2020) | 0.56 |
| " Additionally, these models are able to identify patient characteristics that cause alterations in the expected PK/PD profiles and through simulations can recommend changes to dosing which compensate for the differences." | ( Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations.
Hughes, E; Jagannathan, P; Mohamed Ali, A; Savic, RM; Wallender, E, 2021) | 0.62 |
| " Importantly, this would improve patient compliance due to decrease in dosing frequency as a sustained release formulation." | ( Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration.
Akpa, PA; Attama, AA; Echezona, AC; Ezeibe, EN; Kenechukwu, FC; Momoh, MA; Ugwu, CN; Ugwuoke, JA, 2020) | 0.56 |
| " Dosing is suboptimal in young children." | ( The Impact of Extended Treatment With Artemether-lumefantrine on Antimalarial Exposure and Reinfection Risks in Ugandan Children With Uncomplicated Malaria: A Randomized Controlled Trial.
Aweeka, FT; Colt, M; Goodwin, J; Huang, L; Kajubi, R; Li, F; Mwebaza, N; Orukan, F; Parikh, S; Richards, K; Wang, K; Whalen, ME, 2023) | 0.91 |
| " Participants were randomly allocated 1:1 to antimalarial chemoprophylaxis, a 3-day course of twice-daily artemether-lumefantrine followed by the same daily dosing once a week while travelling in the forest and for a further 4 weeks after leaving the forest (four tablets per dose; 20 mg of artemether and 120 mg of lumefantrine per tablet), or a multivitamin with no antimalarial activity." | ( Antimalarial chemoprophylaxis for forest goers in southeast Asia: an open-label, individually randomised controlled trial.
Callery, JJ; Chotthanawathit, P; Conradis-Jansen, F; Dondorp, AM; Duanguppama, J; Ean, M; Heng, C; Imwong, M; Jongdeepaisal, M; Khonputsa, P; Madmanee, W; Maude, RJ; Mukaka, M; Peerawaranun, P; Pell, C; Peto, TJ; Pongsoipetch, K; Rekol, H; Sokha, M; Sovannaroth, S; Soviet, U; Tarning, J; Tripura, R; von Seidlein, L; Waithira, N; White, NJ, 2023) | 0.91 |
| " However, the optimal choice of medication and dosing for many potential candidates is not clear." | ( Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria.
Dondorp, AM; Maude, RJ; Tarning, J; von Seidlein, L; White, NJ, 2022) | 0.72 |
| " However, the most favourable exposure profile, and arguably most practical dosing scenario, was an initial 3 day full AL treatment course followed by twice daily dosing given once a week for the duration of chemoprevention." | ( Modelling the optimal dosing schedule for artemether-lumefantrine chemoprophylaxis against malaria.
Dondorp, AM; Maude, RJ; Tarning, J; von Seidlein, L; White, NJ, 2022) | 0.72 |
| " Participants were randomly assigned (1:1) to receive single low-dose primaquine combined with either artemether-lumefantrine or dihydroartemisinin-piperaquine, dosed by bodyweight." | ( Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, n
Abongo, G; Basara, BB; Baseke, J; Bongo, GS; Day, NJP; Dhorda, M; Dondorp, AM; Fanello, C; Kayembe, DK; Maitland, K; Muhindo, R; Mukaka, M; Namayanja, C; Ndjowo, PO; Okalebo, CB; Olupot-Olupot, P; Onyamboko, MA; Onyas, P; Peerawaranun, P; Tarning, J; Taya, C; Taylor, WR; Titin, H; Uyoga, S; Waithira, N; Weere, W; Williams, TN, 2023) | 0.91 |
| " Parasite regrowth occurred after dosing with 200 mg (3/3 participants) and 300 mg (3/4 participants) but not after 400 mg or 600 mg." | ( Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum.
Abd-Rahman, AN; Barber, BE; Birrell, GW; Edstein, MD; Leelasena, I; Llewellyn, S; Marquart, L; McCarthy, JS; Moehrle, JJ; Potter, AJ; Sahai, N; Shanks, GD; Webster, R; Wesche, D, 2023) | 0.91 |
| "This retrospective, observational study explored associations between changing malaria service point (health facility or CHW) density per 1000 people and severe malaria admissions or malaria inpatient deaths by district and month in a dose-response approach, using existing routine and programmatic data." | ( Effectiveness of community case management of malaria on severe malaria and inpatient malaria deaths in Zambia: a dose-response study using routine health information system data.
Ashton, RA; Bennett, A; Burnett, S; Eisele, TP; Hainsworth, M; Hamainza, B; Lungu, C; Miller, JM; Porter, T; Rutagwera, MI; Silumbe, K; Slater, H, 2023) | 0.91 |
| " Robust training on appropriate anti-malarial and dosage is needed, particularly given the recent change in recommendation for artemether-lumefantrine use in the first trimester." | ( Healthcare provider and drug dispenser knowledge and adherence to guidelines for the case management of malaria in pregnancy in the context of multiple first-line artemisinin-based combination therapy in western Kenya.
Dellicour, S; Gutman, JR; Hill, J; Ochodo, E; Osoro, CB; Ter Kuile, F; Young, T, 2023) | 0.91 |